摘要
To the Editor： Epidermal growth overexpressed in non-small cell factor receptor （EGFR） is lung cancer （NSCLC） and contains a tyrosine kinase inhibitor （TKI） domain which acts as an important therapeutic target. Previous studies have observed the efficacy of EGFR-TKIs in the most commonly targeted exon mutations （19 and 21）. This study was to investigat the pathologic features of uncommon EGFR mutations and the clinical efficacies of EGFR-TKIs treatment.
To the Editor： Epidermal growth overexpressed in non-small cell factor receptor （EGFR） is lung cancer （NSCLC） and contains a tyrosine kinase inhibitor （TKI） domain which acts as an important therapeutic target. Previous studies have observed the efficacy of EGFR-TKIs in the most commonly targeted exon mutations （19 and 21）. This study was to investigat the pathologic features of uncommon EGFR mutations and the clinical efficacies of EGFR-TKIs treatment.
